After India, I-MAK files legal challenge against Gilead’s hepatitis C drug sofosbuvir in China
Partial Revocation Of EPO Patent On Sofosbuvir, Key For Hepatitis C
Gilead denied patent for hepatitis C drug sofosbuvir in India
Gilead denied patent for hepatitis C drug sofosbuvir in India
Gilead Sciences’ Indian patent request for hepatitis C drug sofosbuvir faces opposition
I-MAK challenges Gilead sofosbuvir patent in India
I-MAK Opposes Patent Application on Hepatitis C Drug Sofosbuvir
Gilead Sofosbuvir Patent Meets Resistance in India
Gilead attempt to secure patent on hepatitis C drug opposed in India